1999 (2) TMI 150 - AT - Central Excise

Summary

The Revenue appealed against the order classifying Ferrous Gluconate Tablets under Central Excise Tariff. The appeal was dismissed as the tablets were not considered patent or proprietary based on the presence of the trade name "REMED" on the label. The decision was based on a Supreme Court ruling. The appeal was rejected.